Emergent BioSolutions Inc...

NYSE: EBS · Real-Time Price · USD
8.85
0.03 (0.34%)
At close: Aug 15, 2025, 3:59 PM
8.80
-0.51%
After-hours: Aug 15, 2025, 06:46 PM EDT

Emergent BioSolutions Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
1.01B 1.05B 1.12B 1.79B
Cost of Revenue
1.00 705.4M 693.7M 757.5M
Gross Profit
305.2M 343.9M 427.2M 1.04B
Operating Income
-108.7M -726.4M -166M 352.6M
Interest Income
n/a n/a n/a n/a
Pretax Income
-142.9M -731.2M -221.7M 314.4M
Net Income
-190.6M -760.5M -223.8M 219.5M
Selling & General & Admin
308M 368.4M 340.3M 348.4M
Research & Development
70.7M 111.4M 193M 234M
Other Expenses
773.6M 564.2M 59.9M 58.5M
Operating Expenses
1.15B 1.04B 593.2M 640.9M
Interest Expense
71M 87.9M 37.3M 34.5M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
1.12B 1.78B 1.29B 1.4B
Income Tax Expense
47.7M 29.3M 2.1M 83.5M
Shares Outstanding (Basic)
53M 51.2M 50.1M 53.5M
Shares Outstanding (Diluted)
53M 51.2M 50.1M 54.1M
EPS (Basic)
-3.6 -14.85 -4.47 4.10
EPS (Diluted)
-3.6 -14.85 -4.47 4.06
EBITDA
36.9M -505.3M -32.9M 458.2M
EBIT
-71.9M -643.3M -181.7M 331.9M
Depreciation & Amortization
108.8M 125.1M 148.9M 126.3M